Nucor earnings beat by $0.08, revenue fell short of estimates
Investing.com - Edwards Lifesciences (NYSE: EW) reported first quarter EPS of $0.64, $0.04 better than the analyst estimate of $0.60. Revenue for the quarter came in at $1.41B versus the consensus estimate of $1.4B.
Guidance
Edwards Lifesciences sees Q2 2025 EPS of $0.59-$0.65 versus the analyst consensus of $0.62.
Edwards Lifesciences sees Q2 2025 revenue of $1.45B-$1.53B versus the analyst consensus of $1.47B.
Edwards Lifesciences sees FY 2025 EPS of $2.40-$2.50 versus the analyst consensus of $2.45.
Edwards Lifesciences’s stock price closed at $70.46. It is up 2.13% in the last 3 months and down -20.48% in the last 12 months.
Edwards Lifesciences saw 11 positive EPS revisions and 6 negative EPS revisions in the last 90 days. See Edwards Lifesciences’s stock price’s past reactions to earnings here.
According to InvestingPro, Edwards Lifesciences’s Financial Health score is "good performance".
Check out Edwards Lifesciences’s recent earnings performance, and Edwards Lifesciences’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar